Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
Xiaofei Zhu,* Fuqi Li,* Dongchen Shi,* Xiaoping Ju,* Yangsen Cao, Yuxin Shen, Fei Cao, Shuiwang Qing, Fang Fang, Zhen Jia, Huojun Zhang Department of Radiation Oncology, Changhai Hospital Affiliated to Navy Medical University, Shanghai, People’s Republic of China *These authors contributed...
Main Authors: | Zhu X, Li F, Shi D, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/health-related-quality-of-life-for-gemcitabine-and-nab-paclitaxel-plus-peer-reviewed-article-CMAR |
Similar Items
-
Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
by: Chiorean EG, et al.
Published: (2018-05-01) -
Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01) -
Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01) -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01) -
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
by: Masashi Sawada, et al.
Published: (2020-05-01)